Clinical research professionals have an obligation to uphold the highest ethical standards and strive for compliance with Good Clinical Practice (GCP). The ALCOA+C definition in ICH E6(R2) has created challenges and uncertainty within the industry with regard to its implementation in a TMF.
Fundamental to these new guidelines is the modernization of processes and technology to clinical trials with a focus on Quality by Design and risk-based management approaches that emphasize operational efficiencies and a movement away from an overreliance on retrospective practices.
In this session we explore:
![]() |
Karen Roy Chief Strategy Officer |
![]() |
Andy Lawton Consultant |
![]() |
Stephanie Mayhew Manager of |
![]() |
Elvin Thalund Director, Industry Strategy Oracle |